New drug combo aims to shrink tough breast tumors before surgery
NCT ID NCT02530489
Summary
This study tested a two-drug combination given before surgery to treat triple-negative breast cancer, a type that can be harder to treat. It involved 37 patients whose cancer did not shrink enough after standard initial chemotherapy. The goal was to see if adding an immunotherapy drug (atezolizumab) to a chemotherapy drug (nab-paclitaxel) could better shrink tumors, potentially allowing for less extensive surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.